Manual Prior Authorization



Eteplirsen (Exondys 51TM) CRITERIA

☐ Diagnosis of Duchenne Muscular Dystrophy (DMD) with mutation amenable to exon 51 skipping; ICD-10 code:
Prior authorization requests for Exondys 51 TM (eteplirsen) may be approved if the following criteria are met: (<i>Yes should be checked for each statement</i>):
☐ Yes ☐ No Males < age 14 years
☐ Yes ☐No Patient has a diagnosis of Duchenne muscular dystrophy (DMD) with mutation amenable to exon 51 skipping <i>confirmed</i> by genetic testing (attach results of genetic testing); and
☐ Yes ☐ No Is prescribed by or in consultation with a physician who specializes in treatment of Duchenne muscular dystrophy; and
☐ Yes ☐ No A baseline 6-Minute Walk Test (6MWT) is provided and patient is able to achieve a distance of at least 180 meters while walking independently; and
\square Yes \square No Patient is currently stable on an oral corticosteroid* regimen for at least 6 months; and
\square Yes \square No Is dosed based on FDA approved dosing: 30 mg/kg once weekly as a 35 to 60 minute intravenous infusion
*The required trials may be overridden when documented evidence is provided that use of these agents would be medically contraindicated.
When criteria for coverage are met, an initial authorization will be given for 6 months.
Requests for continuation of therapy will be considered at 6 month intervals when the following criteria are met:
☐ Yes ☐ No Patient has demonstrated a response to therapy as evidenced by remaining ambulatory (able to walk with or without assistance, not wheelchair dependent); and
☐ Yes ☐ No An updated 6 MWT is provided documenting patient is able to achieve a distance of at least 180 meters.